Alpha 2.0
Login Register
» Articles » PMID: 25947035

Favorable Prognostic Impact of RAS Mutation Status in Multiple Myeloma Treated with High-dose Melphalan and Autologous Stem Cell Support in the Era of Novel Agents: a Single Center Perspective

Overview
Journal Leuk Lymphoma
Specialties Hematology
Oncology
Date 2015 May 8
PMID 25947035
Citations 5
Authors
Niklas Gebauer
Harald Biersack
Ann-Cathrin Czerwinska
Janina Schemme
Tim Tristan Hardel
Veronica Bernard
Dirk Rades
Hendrik Lehnert
Kim Barbara Luley
Christoph Thorns
Affiliations
Soon will be listed here.
Citing Articles

Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis.

Li N, Lin P, Zuo Z, You M, Shuai W, Orlowski R Cancer Med. 2023; 12(13):14293-14304.

PMID: 37212518 PMC: 10358222. DOI: 10.1002/cam4.6103.

Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.

Witte H, Kunstner A, Hertel N, Bernd H, Bernard V, Stolting S Blood Adv. 2021; 6(2):637-651.

PMID: 34714908 PMC: 8791589. DOI: 10.1182/bloodadvances.2021005486.

, , and mutations in plasma cell myeloma at a single Korean institute.

Kim Y, Park S, Min C, Lee G, Son J, Jo S Blood Res. 2020; 55(3):159-168.

PMID: 32989177 PMC: 7536562. DOI: 10.5045/br.2020.2020137.

Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines.

Weissbach S, Heredia-Guerrero S, Barnsteiner S, Grosshans L, Bodem J, Starz H Cancers (Basel). 2020; 12(2).

PMID: 32079091 PMC: 7072554. DOI: 10.3390/cancers12020455.

Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma.

Keppler S, WeiBbach S, Langer C, Knop S, Pischimarov J, Kull M Oncotarget. 2016; 7(25):38762-38774.

PMID: 27246973 PMC: 5122427. DOI: 10.18632/oncotarget.9607.